Samsung Biologics will participate in four major pharmaceutical and biotech events across Japan, Europe, the United States, and Korea throughout October, aiming to secure global clients.
The company announced on October 1 that it will kick off its participation with 'Bio Japan 2026' in Yokohama from October 7 to 9, followed by 'CPhI Milan 2026' in Italy, 'World ADC San Diego' in the U.S., and 'BioPlus Interphex Korea 2026 (BIX)' domestically.
Samsung Biologics has participated in Bio Japan for four consecutive years since 2023. This year, it will again set up a standalone booth to target the Asia-Pacific (APAC) market for contract development and manufacturing organization (CDMO) business. The company plans to highlight its end-to-end CDMO services, which encompass everything from research and development to production, along with its world-leading production capacity.
On the first day of the event, James Choi, Vice President of Sales Support, will present on integrated CDMO services, while Choi Yeon-jeong, a professional in the New Modality Group, will share research results on optimizing antibody-drug conjugate (ADC) coupling processes using computational fluid dynamics (CFD).
From October 6 to 8, Samsung Biologics will also operate a standalone booth at CPhI Milan 2026, where it will meet potential clients, including major global pharmaceutical companies, to showcase its contract manufacturing organization (CMO) capabilities, global production bases, and next-generation multimodality technologies.
In the U.S., the company will participate in World ADC in San Diego from October 12 to 15, promoting its production and development capabilities related to ADCs. It will introduce its technologies through its booth, presentations, and poster sessions. Marc Studer, head of the ADC and mRNA Operations team, will discuss key success factors for ramping up Good Manufacturing Practice (GMP) production of ADCs. Kim Ji-na, head of the ADC Platform Discovery Group, and Oh Se-kyu, a professional in the Organoid Technology Group, will each present research results related to bispecific ADCs and patient-derived organoids in poster format.
Domestically, Samsung Biologics will participate in BIX at COEX in Seoul from October 28 to 30, where Lee Tae-hee, head of the Antibody Cell Purification Process Development Team, will present on strategies for developing bispecific and multispecific antibodies.
Through these four events, Samsung Biologics aims to showcase its production capacity, business portfolio, and global production bases to enhance its CDMO competitiveness. The strategy is to expand its connections with global pharmaceutical and biotech companies to secure new contract opportunities and broaden its business scope.
Meanwhile, Samsung Biologics announced last month that it signed a CMO contract worth $262.18 million with a European pharmaceutical company. The contract is set to last until December 31, 2033. This marks the sixth contract of the year (as per disclosure), bringing Samsung Biologics' cumulative order amount close to 30 trillion won.
This contract is particularly noteworthy as it was successfully secured amid challenging conditions, including global economic uncertainties and intensified competition in the CDMO market, extending through 2033.
The company announced on October 1 that it will kick off its participation with 'Bio Japan 2026' in Yokohama from October 7 to 9, followed by 'CPhI Milan 2026' in Italy, 'World ADC San Diego' in the U.S., and 'BioPlus Interphex Korea 2026 (BIX)' domestically.
Samsung Biologics has participated in Bio Japan for four consecutive years since 2023. This year, it will again set up a standalone booth to target the Asia-Pacific (APAC) market for contract development and manufacturing organization (CDMO) business. The company plans to highlight its end-to-end CDMO services, which encompass everything from research and development to production, along with its world-leading production capacity.
On the first day of the event, James Choi, Vice President of Sales Support, will present on integrated CDMO services, while Choi Yeon-jeong, a professional in the New Modality Group, will share research results on optimizing antibody-drug conjugate (ADC) coupling processes using computational fluid dynamics (CFD).
From October 6 to 8, Samsung Biologics will also operate a standalone booth at CPhI Milan 2026, where it will meet potential clients, including major global pharmaceutical companies, to showcase its contract manufacturing organization (CMO) capabilities, global production bases, and next-generation multimodality technologies.
In the U.S., the company will participate in World ADC in San Diego from October 12 to 15, promoting its production and development capabilities related to ADCs. It will introduce its technologies through its booth, presentations, and poster sessions. Marc Studer, head of the ADC and mRNA Operations team, will discuss key success factors for ramping up Good Manufacturing Practice (GMP) production of ADCs. Kim Ji-na, head of the ADC Platform Discovery Group, and Oh Se-kyu, a professional in the Organoid Technology Group, will each present research results related to bispecific ADCs and patient-derived organoids in poster format.
Domestically, Samsung Biologics will participate in BIX at COEX in Seoul from October 28 to 30, where Lee Tae-hee, head of the Antibody Cell Purification Process Development Team, will present on strategies for developing bispecific and multispecific antibodies.
Through these four events, Samsung Biologics aims to showcase its production capacity, business portfolio, and global production bases to enhance its CDMO competitiveness. The strategy is to expand its connections with global pharmaceutical and biotech companies to secure new contract opportunities and broaden its business scope.
Meanwhile, Samsung Biologics announced last month that it signed a CMO contract worth $262.18 million with a European pharmaceutical company. The contract is set to last until December 31, 2033. This marks the sixth contract of the year (as per disclosure), bringing Samsung Biologics' cumulative order amount close to 30 trillion won.
This contract is particularly noteworthy as it was successfully secured amid challenging conditions, including global economic uncertainties and intensified competition in the CDMO market, extending through 2033.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.